Semaglutide – julymd
US$ 25.31
cardinal health glp-1 receptor agonist weight management diabetes treatments Frontiers Medscape | GLP-1 receptor agonists
Description
The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health
Conflict of interest BG has served as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck (MSD) and Novartis as manufacturers of DPP-4 inhibitors and has received honoraria from these companies for lectures
Gasbjerg, L
The study tracked over 82,000 diabetes patients between 2014 and 2017
A study of orforglipron (LY3502970) in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1)
